<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180719040524N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-07-23</date_registration>
      <primary_sponsor>Rajaie Heart Hospital</primary_sponsor>
      <public_title>The efficacy of neutralizing heparin by prothamine in cardiac open heart surgery</public_title>
      <acronym></acronym>
      <scientific_title>The efficiency and effectiveness of the ACT, ROTEM protocol for neutralizingprotamine heparin in adult patients with open heart surgery (CABG) at ShahidRajaee Cardiovascular Research and Treatment Center</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-10-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/34431</url>
      <study_type>observational</study_type>
      <study_design>Randomization: Not randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Health service research, Blinding description: Patients undergoing surgery are divided into two intervention and control groups that are divided into the knowledge of the medical staff as well as the patients between the two groups, so that the patients do not know which group they are divided into and after entering the operating room.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Heart disease.</hc_freetext>
      <i_freetext>Intervention 1: Our intervention group on the day of operation after taking the anesthetic is taken from the ACT patient at the start of the procedure, and then 3mg / kg heparin is given to prepare the patient for the pump to go. The ACT is acceptable to go to the 420-480sec pump. In order to ensure that this number is taken again, ACT is taken. The pump is also impregnated with 100 milligrams of heparin to prevent the possibility of blood coagulation in the pump ducts. After the patient goes to the pump half an hour later, we take another ACT. And then, depending on the duration of the action, if the discretion and necessity of every hour, an ACT is taken from the patient. At the end of the operation, when you want Let's warm the patient and bring her body temperature to 36.5 degrees from the ROTEM patient as well as the ACT before the pump is turned off. When the patient is transferred to the ICU (ACT), ACT is taken and one hour later if We look at the bleeding from the ROTEM patient in order to investigate the underlying cause. According to this protocol, we try to achieve the optimal dose of heparin and protamine and the dose of the two for the patient from the amount of unwanted bleeding at the end of the patient. Practicing and wasteful use of industrial products. Intervention 2: Control group: Our control group is selected on the basis of anesthesiologists' and epidemiologist's discretion and placed on the routine of the operating room under anesthesia and attached to the pump.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Part of the extracted data from patient analyzes after unidentifiable patients for sharing is possible.

When:
The publication time of the documentation is considered 3 months after the publication of the results

To whom:
Access to data is only possible for researchers and professors working in health centers.

Conditions:
Only a review request for use in future investigations will be allowed.

Where to obtain:
1-email: aliasghaffari@gmail.com
2-Mobile: 09126718543; Ali Ghaffari

How to obtain:
Upon request, the applicant receives documentation about 3 months from the date of receipt of the documentation

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Seyed Mostafa Alavi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Rajaie Heart Hospital ;Hashemi Rafsanjani Hwy</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1115119969</zip>
        <telephone>+98 21 23921</telephone>
        <email>aliasghaffari@gmail.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Seyed Mostafa Alavi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Rajaie Heart Hospital;Hashemi Rafsanjani Hwy</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1115119969</zip>
        <telephone>+98 21 23921</telephone>
        <email>aliasghaffari@gmail.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients who do not have an anticoagulant drug
Patients undergoing surgery for the first time</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with a history of heart surgery
Patients with coagulation disorders
Patients with liver and kidney failure</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I70</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Atherosclerosis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Our intervention group on the day of operation after taking the anesthetic is taken from the ACT patient at the start of the procedure, and then 3mg / kg heparin is given to prepare the patient for the pump to go. The ACT is acceptable to go to the 420-480sec pump. In order to ensure that this number is taken again, ACT is taken. The pump is also impregnated with 100 milligrams of heparin to prevent the possibility of blood coagulation in the pump ducts. After the patient goes to the pump half an hour later, we take another ACT. And then, depending on the duration of the action, if the discretion and necessity of every hour, an ACT is taken from the patient. At the end of the operation, when you want Let's warm the patient and bring her body temperature to 36.5 degrees from the ROTEM patient as well as the ACT before the pump is turned off. When the patient is transferred to the ICU (ACT), ACT is taken and one hour later if We look at the bleeding from the ROTEM patient in order to investigate the underlying cause. According to this protocol, we try to achieve the optimal dose of heparin and protamine and the dose of the two for the patient from the amount of unwanted bleeding at the end of the patient. Practicing and wasteful use of industrial products.</i_keyword>
      <i_keyword>Control group: Our control group is selected on the basis of anesthesiologists' and epidemiologist's discretion and placed on the routine of the operating room under anesthesia and attached to the pump.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>To investigate more precisely the blood factors and the results of neutralizing the effects of anticoagulant drugs used during surgery, we use the ROTEM device. Timepoint: At the end of the operation, if necessary, an observer will be used. Method of measurement: By ROTEM.</prim_outcome>
      <prim_outcome>Our primary variable is the patient's activated clotting time (ACT). Timepoint: ACT is taken from the beginning of the surgery every hour and ACT is taken at the end of the operation, after neutralizing the effect of heparin ACT. Method of measurement: Measured by ACT.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Rajaie Heart Hospital</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-11-06</approval_date>
        <contact_name>Ethics Committee, Faculty of Pharmacy and Pharmaceutical Sciences, Islamic Azad University of Medica</contact_name>
        <contact_address>No.24;38 street;shahr ara street tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
